MCID: NVS001
MIFTS: 53

Neovascular Glaucoma

Categories: Eye diseases, Fetal diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Neovascular Glaucoma

MalaCards integrated aliases for Neovascular Glaucoma:

Name: Neovascular Glaucoma 12 58 15 17
Glaucoma, Neovascular 43 71
Secondary Angle-Closure Glaucoma with Rubeosis 12
Glaucoma Neovascular 54

Characteristics:

Orphanet epidemiological data:

58
neovascular glaucoma
Prevalence: 1-5/10000 (Europe);

Classifications:

Orphanet: 58  
Rare eye diseases
Developmental anomalies during embryogenesis


External Ids:

Disease Ontology 12 DOID:1687
MeSH 43 D015355
SNOMED-CT 67 232086000
MESH via Orphanet 44 D015355
UMLS via Orphanet 72 C0017609
Orphanet 58 ORPHA94058
UMLS 71 C0017609

Summaries for Neovascular Glaucoma

Disease Ontology : 12 A glaucoma characterized by narrowing of the anterior chamber angle secondary to neovascularization along the iris and iridocorneal angle such that the aqueous fluid outflow is blocked and intraocular pressure becomes inappropriately elevated leading to optic nerve damage and visual field loss. Neovascular glaucoma has symptom progressive peripheral vision loss, decreased vision, and pain, redness, and headache in acute cases. Neovascular glaucoma can be related to abnormal angiogenesis with ischemic retinal diseases, inflammation, diabetes mellitus, intraocular malignancy, and autoinmmune diseases.

MalaCards based summary : Neovascular Glaucoma, also known as glaucoma, neovascular, is related to intraocular pressure quantitative trait locus and central retinal vein occlusion, and has symptoms including progressive peripheral vision loss An important gene associated with Neovascular Glaucoma is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Travoprost and Acetazolamide have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotypes are glaucoma and visual loss

Related Diseases for Neovascular Glaucoma

Diseases related to Neovascular Glaucoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 268)
# Related Disease Score Top Affiliating Genes
1 intraocular pressure quantitative trait locus 31.9 VEGFA TGFB2 PEX19 CRYAA
2 central retinal vein occlusion 31.6 VEGFA PLG PGF
3 rubeosis iridis 31.5 VEGFA PLG
4 retinal vein occlusion 31.3 VEGFA KDR CXCL8
5 retinal ischemia 31.1 VEGFA FGF2 CRYAA
6 branch retinal artery occlusion 31.0 VEGFA PLG CRYAA
7 microvascular complications of diabetes 1 30.9 VEGFA TGFB2 FLT1 FGF2 CXCL8
8 central retinal artery occlusion 30.9 VEGFA PLG CRYAA
9 glaucoma, primary open angle 30.7 TGFB2 PEX19 CRYAA
10 uveitis 30.6 TGFB2 CXCL8 CRYAA CAPN5
11 melanoma, uveal 30.4 VEGFA TGFB2 PLG CRYAA
12 keratitis, hereditary 30.4 VEGFA FGF2 CRYAA
13 coats disease 30.3 VEGFA RS1 KDR
14 retinal detachment 30.2 VEGFA TGFB2 RS1 FGF2 CXCL8 CAPN5
15 malignant ciliary body melanoma 30.2 VEGFD FLT1
16 cataract 30.2 VEGFA TJP1 TGFB2 FGF2 CXCL8 CRYAA
17 mature cataract 30.0 PEX19 CRYAA
18 moyamoya disease 1 29.9 VEGFA PLG FGF2
19 acute closed-angle glaucoma 29.9 PEX19 CIAO3
20 macular holes 29.7 VEGFA TGFB2 RS1 PLG CRYAA
21 microvascular complications of diabetes 5 29.7 VEGFA TGFB2 PLG PGF KDR FLT1
22 endophthalmitis 29.6 VEGFB VEGFA PLG PGF FLT1 CXCL8
23 hemangioma 29.6 VEGFA KDR FLT1 FGF2
24 background diabetic retinopathy 29.6 VEGFB VEGFA PGF KDR
25 diabetic macular edema 29.5 VEGFB VEGFA PGF FLT1 FGF2
26 retinal artery occlusion 29.4 VEGFB VEGFA PLG PGF KDR FLT1
27 capillary hemangioma 29.4 VEGFA KDR FLT1 FGF2
28 myeloma, multiple 29.0 VEGFA KDR FLT1 FGF2 CXCL8
29 macular retinal edema 29.0 VEGFB VEGFA TJP1 PGF KDR FLT1
30 eye disease 28.7 VEGFA TGFB2 RS1 PGF KDR FLT1
31 diabetes mellitus, noninsulin-dependent 28.7 VEGFA UCP2 PLG PGF CXCL8 CRYAA
32 retinal vascular occlusion 28.5 VEGFB VEGFA PLG PGF KDR FLT1
33 retinal vascular disease 28.4 VEGFB VEGFA PLG PGF KDR FLT1
34 hypertension, essential 28.1 VEGFA UCP2 PLG PGF KDR FLT1
35 kuhnt-junius degeneration 28.0 VEGFD VEGFB VEGFA PLG PGF KDR
36 macular degeneration, age-related, 1 27.0 VEGFD VEGFB VEGFA TJP1 TGFB2 RS1
37 retinoschisis 1, x-linked, juvenile 11.6
38 microvascular complications of diabetes 2 10.8
39 blind hypotensive eye 10.5
40 open-angle glaucoma 10.4
41 fuchs' heterochromic uveitis 10.4 TGFB2 CXCL8
42 bullous retinoschisis 10.4 VEGFA RS1
43 microcystic meningioma 10.4 VEGFA FLT1
44 yemenite deaf-blind hypopigmentation syndrome 10.4
45 lipodermatosclerosis 10.4 VEGFA FLT1
46 vitreoretinal dystrophy 10.4 RS1 CRYAA
47 glomeruloid hemangioma 10.4 VEGFA FLT1
48 preretinal fibrosis 10.4 VEGFA TGFB2
49 ocular hypertension 10.4
50 upper lip cancer 10.3 TGFB2 FGF2

Graphical network of the top 20 diseases related to Neovascular Glaucoma:



Diseases related to Neovascular Glaucoma

Symptoms & Phenotypes for Neovascular Glaucoma

Human phenotypes related to Neovascular Glaucoma:

58 31 (show all 16)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 glaucoma 58 31 obligate (100%) Obligate (100%) HP:0000501
2 visual loss 58 31 hallmark (90%) Very frequent (99-80%) HP:0000572
3 iris neovascularization 58 31 hallmark (90%) Very frequent (99-80%) HP:0011497
4 retinal vein occlusion 58 31 hallmark (90%) Very frequent (99-80%) HP:0012636
5 photophobia 58 31 frequent (33%) Frequent (79-30%) HP:0000613
6 abnormality of the optic nerve 58 31 frequent (33%) Frequent (79-30%) HP:0000587
7 visual acuity test abnormality 58 31 frequent (33%) Frequent (79-30%) HP:0030532
8 ocular hypertension 58 31 frequent (33%) Frequent (79-30%) HP:0007906
9 ocular pain 58 31 frequent (33%) Frequent (79-30%) HP:0200026
10 abnormality of central retinal artery 58 31 frequent (33%) Frequent (79-30%) HP:3000032
11 retinal vascular proliferation 58 31 occasional (7.5%) Occasional (29-5%) HP:0007850
12 abnormal anterior chamber morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0000593
13 corneal stromal edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0012040
14 retinal detachment 58 31 very rare (1%) Very rare (<4-1%) HP:0000541
15 abnormal uvea morphology 58 Frequent (79-30%)
16 abnormality of the posterior segment of the globe 58 Occasional (29-5%)

Symptoms:

12
  • progressive peripheral vision loss

MGI Mouse Phenotypes related to Neovascular Glaucoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.02 FGF2 FLT1 KDR PGF PLG TGFB2
2 growth/size/body region MP:0005378 10 CAPN5 FLT1 KDR PGF PLG TGFB2
3 mortality/aging MP:0010768 9.93 CAPN5 CIAO3 FGF2 FLT1 KDR PLG
4 nervous system MP:0003631 9.65 FGF2 FLT1 KDR PLG RS1 TGFB2
5 vision/eye MP:0005391 9.28 FGF2 FLT1 KDR PGF PLG RS1

Drugs & Therapeutics for Neovascular Glaucoma

Drugs for Neovascular Glaucoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Travoprost Approved Phase 4 157283-68-6 5282226
2
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
3
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
4
Dorzolamide Approved Phase 4 120279-96-1 5284549 3154
5
Timolol Approved Phase 4 26839-75-8 5478 33624
6
tannic acid Approved Phase 4 1401-55-4
7
Brinzolamide Approved Phase 4 138890-62-7 68844
8
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
9
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
10 Antihypertensive Agents Phase 4
11 Anesthetics Phase 4
12 Immunoglobulins Phase 4
13 Antibodies Phase 4
14 Antibodies, Monoclonal Phase 4
15 Adrenergic alpha-Agonists Phase 4
16 Adrenergic beta-Antagonists Phase 4
17 Adrenergic Agents Phase 4
18 Ophthalmic Solutions Phase 4
19 Adrenergic Agonists Phase 4
20 Carbonic Anhydrase Inhibitors Phase 4
21 Brimonidine Tartrate Phase 4 70359-46-5
22 Neurotransmitter Agents Phase 4
23 Antineoplastic Agents, Immunological Phase 4
24
Ranibizumab Approved Phase 3 347396-82-1 459903
25
Triamcinolone Approved, Vet_approved Phase 2, Phase 3 124-94-7 31307
26
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
27
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
28 Insulin, Globin Zinc Phase 2, Phase 3
29 insulin Phase 2, Phase 3
30 Mitomycins Phase 2, Phase 3
31 Angiogenesis Inhibitors Phase 2, Phase 3
32 Hormone Antagonists Phase 2, Phase 3
33 Hormones Phase 2, Phase 3
34 glucocorticoids Phase 2, Phase 3
35 Triamcinolone diacetate Phase 2, Phase 3
36 Triamcinolone hexacetonide Phase 2, Phase 3
37 triamcinolone acetonide Phase 2, Phase 3
38 Anti-Inflammatory Agents Phase 2, Phase 3
39 Immunologic Factors Phase 2, Phase 3
40 Pharmaceutical Solutions Phase 2, Phase 3
41 Immunosuppressive Agents Phase 2, Phase 3
42 Alkylating Agents Phase 2, Phase 3
43 Anti-Bacterial Agents Phase 2, Phase 3
44 Antibiotics, Antitubercular Phase 2, Phase 3
45 Gentamicins Phase 2, Phase 3
46 Antimetabolites Phase 2, Phase 3
47 Mitogens Phase 3
48 Endothelial Growth Factors Phase 3
49
Bevacizumab Approved, Investigational Phase 2 216974-75-3
50
Epinephrine Approved, Vet_approved 51-43-4 5816

Interventional clinical trials:

(show top 50) (show all 60)
# Name Status NCT ID Phase Drugs
1 Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves Unknown status NCT01883856 Phase 4
2 Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves Unknown status NCT01535768 Phase 4 Aqueous Suppressant Eye Drops
3 Management of Active and Established Corneal Neovascularisation to Prevent Visual Impairment Unknown status NCT02594423 Phase 4 Bevacizumab
4 Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma Completed NCT02647515 Phase 4 ranibizumab
5 Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma Completed NCT01922154 Phase 4 intravitreal ranibizumab
6 The RAVE (Rubeosis Anit-VEgf) Trial, Utilizes Monthly Intravitreal Bevazizumab (Avastin) Injections for 12 Months to See if Total VEGF Blockade Will Prevent Neovascular Glaucoma and Eliminate the Need for Panretinal Photocoagulation in Patients With Ischemic Central Retinal Vein Occlusion Completed NCT00557232 Phase 4 bevacizumab
7 Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study Unknown status NCT02914626 Phase 3 Intravitreal ranibizumab
8 Prospective, Randomised, Placebo-controlled, Double-masked, Three-armed Multi-centre Trial of Aganirsen Versus Vehicle in Patients After Ischaemic Central Retinal Vein Occlusion With a High Risk to Develop Neovascular Glaucoma Unknown status NCT02947867 Phase 2, Phase 3 aganirsen
9 Ahmed Valve Glaucoma Implant With Adjunctive Subconjunctival Bevacizumab in Refractory Glaucoma: a Randomized Controlled Clinical Trial Unknown status NCT01128699 Phase 3 Subconjunctival Avastin
10 A Randomized, Double-masked, and Controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravitreal Administration of Aflibercept in Japanese Patients With Neovascular Glaucoma Completed NCT02396316 Phase 3 Aflibercept (Eylea, BAY 86-5321);Sham Injection
11 A Single-arm, Non-randomized and Open-label Phase 3 Study Evaluating the Efficacy, Safety and Tolerability of Intravitreal Aflibercept in Japanese Patients With Neovascular Glaucoma (NVG) Completed NCT03639675 Phase 3 Aflibercept (EYLEA, BAY86-5321);Topical IOP-lowering drugs
12 The Effect of Intracameral Triesence (Triamcinolone Acetonide Injectable Suspension) on Ocular Inflammation After Trabeculectomy, Tube Shunt Implantation or Combined Trabeculectomy With Cataract Surgery Completed NCT00853905 Phase 2, Phase 3 Triesence;balanced salt solution BSS
13 An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. Completed NCT01908816 Phase 3 ranibizumab
14 Comprative Study of the Safety and Effectiveness Between Oculusgen (Ologen) Collagen Matrix Implant and Mitomycin-C in Glaucoma Filtering Surgery Completed NCT00524758 Phase 3 MMC in Trabeculectomy
15 Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis Completed NCT02641457 Phase 3 Aflibercept;Ranibizumab
16 Treatment With Anti-vascular Endothelial Growth Factor in Patients With Branch Retinal Vein Occlusion: 5 Years of Clinical Experience Completed NCT02033031 Phase 3 Lucentis intravitreal injection;Avastin intravitreal injection
17 Central Vein Occlusion Study (CVOS) Completed NCT00000131 Phase 3
18 An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy Completed NCT00996437 Phase 2, Phase 3 Ranibizumab;Saline
19 Bevacizumab Versus Mitomycin C as Trabeculectomy Adjuvant in Uncontrolled Glaucoma: A Randomized Pilot Trial. Completed NCT02901236 Phase 2, Phase 3 Mitomycin C;Bevacizumab
20 Randomized Trial Evaluating Bevacizumabe or Triamcinolone for Persistent Diabetic Macular Edema Completed NCT02985619 Phase 2, Phase 3 Bevacizumab;Triamcinolone Acetonide
21 Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-Vascular Endothelial Growth Factor in Patients Treated With Proton Therapy for a Large Choroidal Melanoma Not yet recruiting NCT03172299 Phase 3 Aflibercept Injection;False injection
22 Analysis of Vitreous and Aqueous Humor for Ocular Growth Factors, Cytokines, Chemokines, and Ranibizumab Pharmacokinetics Associated With Various Retinal Disease Unknown status NCT02067013 Phase 2 Ranibizumab
23 Intravitreal Avastin Versus Intravitreal Avastin and Triamcinolone in Central Retinal Vein Occlusion(CRVO) Unknown status NCT00370630 Phase 2 Avastin (Bevacizumab) and triamcinolone
24 The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Patients With Diabetic Retinopathy Unknown status NCT03006081 Phase 2 Intravitreal Aflibercept injection
25 Does Hyperbaric Chamber Improve the Functionality and Symptoms Related to Central Retinal Vein Occlusion (CRVO)? Unknown status NCT02405741 Phase 2
26 Avastin as an Adjunct to Diode Laser Cyclophotoablation in the Treatment of Neovascular Glaucoma Completed NCT01051583 Phase 2
27 Lucentis in the Treatment of Macular Edema - A Phase II, Single Center, Randomized Study to Evaluate the Efficacy of Ranibizumab Versus Focal Laser Treatment in Subjects With Diabetic Macular Edema Completed NCT00387582 Phase 2 Ranibizumab (Lucentis)
28 Phase 2 Ziv-aflibercept in Ocular Disease Short and Long-term Study Recruiting NCT02486484 Phase 2 ziv-aflibercept
29 Ahmed Glaucoma Valve Surgery With Mitomycin-C Active, not recruiting NCT02805257 Phase 2 Mitomycin-C
30 Randomized Controlled Trial of Lucentis in the Management of New Onset Neovascular Glaucoma Withdrawn NCT00727038 Phase 1, Phase 2 Ranibizumab (Lucentis)
31 A Phase I Single Center Study of Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma Completed NCT00765921 Phase 1 ranibizumab
32 Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion Completed NCT00406471 Phase 1 Ranibizumab (Lucentis)
33 A Phase I Open Label Study of the Safety, Tolerability and Efficacy of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2) Terminated NCT01225146 Phase 1 ranibizumab
34 Comparative Study of the Safety and Efficacy of the Ahmed Glaucoma Valve Drainage Device, Model M4 (High Density Porous Polyethylene) and the Model S2 (Polypropylene) in Patients With Neovascular Glaucoma Unknown status NCT02260219
35 Comparison of Efficacy Between Silicone Ahmed Glaucoma Valves With and Without Intravitreal Triamcinolone Injection Unknown status NCT00491712
36 Comparative,Randomized Study Between Intravitreal Triamcinolone Acetonide and Air-Fluid Exchange in Eyes With Post Vitrectomy Diabetic Vitreous Hemorrhage Unknown status NCT00300014
37 Correlation Between the Visual Acuity and the OCT Pattern of Macular Edema Secondary to Retinal Vein Occlusion Unknown status NCT03489915
38 Adjunctive Triamcinolone Acetonide for Ahmed Glaucoma Valve Implantation Unknown status NCT02653963 Adjunctival Triamcinolone
39 Intravitreal Bevacizumab for Neovascular Glaucoma; a Randomized Placebo Controlled Clinical Trial Completed NCT00384631 Avastin
40 An Open Label, Prospective, Monocenter, Prove of Concept Study to Evaluate the Short- and Long-term Effects of 0.5mg Intraocular Ranibizumab (Lucentis) Injections as Adjuvant for Patients With Rubeosis and Neovascular Glaucoma Completed NCT01370135 0.5mg intraocular Ranibizumab (Lucentis)
41 The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma Completed NCT03154892
42 Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma Completed NCT01711879 Aflibercept
43 One- Year Follow up of Two Models of Ahmed Glaucoma Valves (S2 and FP7) in Refractory Glaucoma Completed NCT04214847
44 Triple Procedure for Dense Cataractus Neovascular Glaucoma Patients Completed NCT04143620
45 Baerveldt Glaucoma Implant Versus Ahmed Glaucoma Implant in One- Year Follow up, Comparative Study Completed NCT04215575
46 Clinical Trial Comparing Subconjunctival and Topical Bevacizumab as Adjuncts to Trabeculectomy in Improving Outcomes for Primary Open Angle Glaucoma Completed NCT01425112
47 A Randomized Trial of the Pops-titration Versus the Slow-coagulation Energy Delivery Technique on the Outcome of Diode Laser Transcleral Cyclophotocoagulation in Treatment of Neovascular Glaucoma With Dark Iris Completed NCT01774227
48 Compliance to Ophthalmic Follow-up Examinations Affect Outcome of Vitrectomy for Proliferative Diabetic Retinopathy Completed NCT01307072
49 Bevacizumab (Avastin) as an Adjunct to Vitrectomy in the Management of Severe Proliferative Diabetic Retinopathy: a Prospective Case Series Completed NCT01041690 Bevacizumab
50 Objective Measurement of Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With a Vascular Endothelial Growth Factor Inhibitor. Completed NCT01360385

Search NIH Clinical Center for Neovascular Glaucoma

Cochrane evidence based reviews: glaucoma, neovascular

Genetic Tests for Neovascular Glaucoma

Anatomical Context for Neovascular Glaucoma

MalaCards organs/tissues related to Neovascular Glaucoma:

40
Eye, Endothelial, Retina, Testes, Lung, B Cells, Myeloid

Publications for Neovascular Glaucoma

Articles related to Neovascular Glaucoma:

(show top 50) (show all 1602)
# Title Authors PMID Year
1
Aqueous humor endothelin-1 (Et-1), vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) levels in Mexican glaucomatous patients. 54 61
20373895 2010
2
Concentration of vascular endothelial growth factor after intracameral bevacizumab injection in eyes with neovascular glaucoma. 54 61
19794946 2009
3
Level of vascular endothelial growth factor in aqueous humor and surgical results of ahmed glaucoma valve implantation in patients with neovascular glaucoma. 61 54
19680051 2009
4
Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. 54 61
18617542 2009
5
Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. 54 61
17700285 2007
6
[The change of the level of the vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma before and after anterior retinal cryotherapy]. 54 61
17897552 2007
7
[Inhibition of angiogenesis in the anterior chamber of the eye]. 54 61
17372736 2007
8
Increased levels of transforming growth factor-betal and -beta2 in the aqueous humor of patients with neovascular glaucoma. 54 61
17278530 2007
9
Transforming growth factor-beta levels in human aqueous humor of glaucomatous, diabetic and uveitic eyes. 61 54
17004630 2006
10
Vascular endothelial growth factor is increased in aqueous humor of glaucomatous eyes. 61 54
12362079 2002
11
[Vascular endothelial growth factor levels in the aqueous and serum in diabetic retinopathy with or without neovascular glaucoma]. 61 54
9852717 1998
12
Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. 61 54
9479280 1998
13
Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. 61 54
8694732 1996
14
Glaucoma as the presenting sign of intraocular tumors: beware of the masquerading sign. 61
32198607 2020
15
Successful treatment of ciliary body medulloepithelioma with intraocular melphalan chemotherapy: a case report. 61
32552699 2020
16
Neovascular glaucoma in patients with central retinal vein occlusion: A real-life study in the anti-VEGF era. 61
32548981 2020
17
Plaque radiation for ciliary body medulloepithelioma presenting with neovascular glaucoma and vitreous hemorrhage in 13-year-old Asian girl. 61
32373758 2020
18
Intravitreal Conbercept Injection as an Adjuvant in Vitrectomy with Silicone Oil Infusion for Severe Proliferative Diabetic Retinopathy. 61
32186940 2020
19
Dose-response and normal tissue complication probabilities after proton therapy for choroidal melanomas. 61
32574763 2020
20
Serous retinal detachment accompanied by pachychoroid in hypotony maculopathy after trabeculectomy for diabetic neovascular glaucoma. 61
32280809 2020
21
Chronic retinal detachment and neovascular glaucoma after intravitreal stem cell injection for Usher Syndrome. 61
32211560 2020
22
Ocular decompression retinopathy following intracameral bevacizumab injection in a case of proliferative diabetic retinopathy with neovascular glaucoma. 61
32461484 2020
23
Rituximab-Associated Retinal Occlusive Vasculopathy: A Case Report and Literature Review. 61
31314626 2020
24
Large B-cell lymphoma of the uvea: Histopathologic variants and clinicopathologic correlation. 61
31676312 2020
25
Expression of platelet-derived growth factor-C in aqueous humor of patients with neovascular glaucoma and its correlation with vascular endothelial growth factor. 61
30803266 2020
26
Clinical practice preferences for glaucoma surgery in Japan: a survey of Japan Glaucoma Society specialists. 61
32474840 2020
27
Aqueous Inflammation and Ischemia-Related Biomarkers in Neovascular Glaucoma with Stable Iris Neovascularization. 61
32339463 2020
28
Assessment of efficacy and safety of micropulse diode laser treatment in glaucoma: One year follow-up. 61
32409244 2020
29
Eyeing the Extracellular Matrix in Vascular Development and Microvascular Diseases and Bridging the Divide between Vascular Mechanics and Function. 61
32429045 2020
30
Anti-Vascular Endothelial Growth Factor Therapy for Radiation Retinopathy. 61
32348534 2020
31
[Whole course management is the key to retinal vein occlusion]. 61
32306615 2020
32
Trabeculectomy in an unsuspected extramedullary iris-ciliary body plasmacytoma. 61
32314602 2020
33
Severe vaso-occlusive lupus retinopathy in the early stage of a pediatric patient with systemic lupus erythematosus: a case report. 61
32312013 2020
34
Metastatic Lung Cancer Masquerading as Endophthalmitis. 61
32236164 2020
35
Impact of uveal melanoma thickness on post-plaque radiotherapy outcomes in the prophylactic anti-vascular endothelial growth factor era in 1131 patients. 61
32277560 2020
36
Recurrent retinal detachment after diabetic vitrectomy. 61
32297051 2020
37
Unusual Association of Inverse Retinitis Pigmentosa, Scleromalacia, and Neovascular Glaucoma. 61
32367703 2020
38
Trend of Neovascular Glaucoma in Taiwan: A 15-year Nationwide Population-based Cohort Study. 61
32326791 2020
39
Neovascular glaucoma in a pediatric patient with neurofibromatosis type 1: a case report. 61
32345252 2020
40
Comment on: Predictors of Neovascular Glaucoma in Central Retinal Vein Occlusion. 61
32005485 2020
41
Reply to Comment on: Predictors of Neovascular Glaucoma in Central Retinal Vein Occlusion. 61
32057368 2020
42
Anomalous retinal artery associated with branch retinal artery occlusion and neovascular glaucoma: A case report. 61
32190636 2020
43
Gamma Knife Radiosurgery for Uveal Melanoma: A Retrospective Review of Clinical Complications in a Tertiary Referral Center. 61
32258019 2020
44
Increased expression of periostin and tenascin-C in eyes with neovascular glaucoma secondary to PDR. 61
31863397 2020
45
Intravitreous Cutaneous Metastatic Melanoma in the Era of Checkpoint Inhibition: Unmasking and Masquerading. 61
31708274 2020
46
Anti-vascular endothelial growth factor for neovascular glaucoma. 61
32027392 2020
47
Angiogenic and inflammatory biomarker levels in aqueous humor and vitreous of neovascular glaucoma and proliferative diabetic retinopathy. 61
31802372 2020
48
Recent epidemiological status of ocular and other major complications related to diabetes mellitus in Japan. 61
32097907 2020
49
Immunohistochemical and Immunocytochemical Analyses in Patients with Vitreoretinal Lymphoma. 61
30335535 2020
50
Altered Intrinsic Functional Connectivity of the Primary Visual Cortex in Patients with Neovascular Glaucoma: A Resting-State Functional Magnetic Resonance Imaging Study. 61
32021196 2020

Variations for Neovascular Glaucoma

Expression for Neovascular Glaucoma

Search GEO for disease gene expression data for Neovascular Glaucoma.

Pathways for Neovascular Glaucoma

Pathways related to Neovascular Glaucoma according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.8 VEGFD VEGFB VEGFA TGFB2 PGF KDR
2
Show member pathways
13.66 VEGFD VEGFB VEGFA TGFB2 PGF KDR
3
Show member pathways
13.51 VEGFD VEGFB VEGFA TGFB2 PGF KDR
4
Show member pathways
13.39 VEGFD VEGFB TGFB2 PGF KDR FLT1
5
Show member pathways
13.29 VEGFD VEGFB TGFB2 PGF KDR FLT1
6
Show member pathways
13.27 VEGFD VEGFB TJP1 TGFB2 PGF KDR
7
Show member pathways
13.24 VEGFD VEGFB VEGFA TGFB2 PGF KDR
8
Show member pathways
13.05 VEGFD VEGFB TGFB2 PGF KDR FLT1
9
Show member pathways
13.03 VEGFD VEGFB TGFB2 PGF KDR FLT1
10
Show member pathways
12.96 VEGFD VEGFB VEGFA PGF KDR FLT1
11
Show member pathways
12.89 VEGFD VEGFB VEGFA PGF KDR FLT1
12 12.83 VEGFD VEGFB VEGFA TGFB2 PGF FGF2
13
Show member pathways
12.72 TGFB2 PLG KDR FGF2 CAPN5
14
Show member pathways
12.7 VEGFD VEGFB VEGFA PGF KDR FLT1
15
Show member pathways
12.66 VEGFD VEGFB TGFB2 PGF KDR FLT1
16 12.59 VEGFD VEGFB VEGFA TGFB2 PGF KDR
17
Show member pathways
12.5 VEGFB VEGFA KDR FLT1 FGF2
18
Show member pathways
12.42 VEGFD VEGFB VEGFA PGF KDR FLT1
19
Show member pathways
12.38 VEGFD VEGFB TGFB2 PGF KDR FLT1
20
Show member pathways
12.38 VEGFD VEGFB VEGFA KDR FLT1 FGF2
21 12.28 VEGFA TGFB2 KDR FGF2
22 12.12 VEGFB KDR FLT1 FGF2
23
Show member pathways
11.92 VEGFA KDR FLT1
24 11.92 VEGFA FGF2 CXCL8
25 11.88 VEGFD VEGFB VEGFA TGFB2 CXCL8
26 11.87 VEGFA TGFB2 FLT1 CXCL8
27
Show member pathways
11.82 VEGFB VEGFA PGF KDR FLT1
28 11.78 VEGFB TGFB2 KDR FLT1 FGF2
29
Show member pathways
11.77 VEGFD VEGFB TGFB2 PGF KDR FLT1
30 11.73 VEGFD VEGFB TGFB2 PGF FGF2
31 11.69 VEGFA TGFB2 KDR FLT1
32 11.66 VEGFA TGFB2 FGF2
33 11.57 VEGFD VEGFB VEGFA
34 11.49 VEGFA KDR FGF2
35 11.35 VEGFA KDR FLT1
36 11.34 VEGFA TGFB2 PLG KDR FGF2
37 11.21 VEGFA FLT1 FGF2
38 11.19 VEGFB VEGFA KDR FLT1 FGF2
39 11.09 VEGFA KDR FLT1 FGF2
40 10.87 VEGFD VEGFB TGFB2 PGF KDR FLT1
41 10.63 VEGFB VEGFA
42
Show member pathways
10.3 VEGFD VEGFB VEGFA PGF KDR FLT1

GO Terms for Neovascular Glaucoma

Cellular components related to Neovascular Glaucoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.85 VEGFD VEGFB VEGFA TGFB2 RS1 PLG
2 extracellular region GO:0005576 9.7 VEGFD VEGFB VEGFA TGFB2 RS1 PLG
3 platelet alpha granule lumen GO:0031093 9.02 VEGFD VEGFB VEGFA TGFB2 PLG

Biological processes related to Neovascular Glaucoma according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 multicellular organism development GO:0007275 10.15 VEGFD VEGFA RS1 PGF KDR FLT1
2 cell differentiation GO:0030154 10.13 VEGFD VEGFA PGF KDR FLT1 FGF2
3 positive regulation of cell proliferation GO:0008284 10.07 VEGFD VEGFA TGFB2 PGF KDR FLT1
4 response to hypoxia GO:0001666 10.02 VEGFD VEGFB VEGFA UCP2 TGFB2 PGF
5 angiogenesis GO:0001525 10.01 VEGFD VEGFB VEGFA PGF KDR FLT1
6 response to drug GO:0042493 9.96 VEGFB TJP1 TGFB2 PGF
7 negative regulation of gene expression GO:0010629 9.96 VEGFA TGFB2 KDR FGF2
8 positive regulation of cell migration GO:0030335 9.93 VEGFA TJP1 KDR FLT1
9 positive regulation of protein phosphorylation GO:0001934 9.93 VEGFD VEGFB VEGFA PGF KDR
10 platelet degranulation GO:0002576 9.91 VEGFD VEGFB VEGFA TGFB2 PLG
11 positive regulation of endothelial cell proliferation GO:0001938 9.91 VEGFD VEGFB VEGFA PGF KDR FGF2
12 positive chemotaxis GO:0050918 9.89 VEGFD VEGFB VEGFA PGF FGF2
13 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.85 VEGFD VEGFB VEGFA PGF KDR FLT1
14 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.81 TGFB2 KDR FLT1
15 hematopoietic progenitor cell differentiation GO:0002244 9.8 KDR FLT1 CIAO3
16 positive regulation of cell division GO:0051781 9.8 VEGFD VEGFB VEGFA TGFB2 PGF FGF2
17 positive regulation of MAP kinase activity GO:0043406 9.79 VEGFA FLT1 FGF2
18 positive regulation of blood vessel endothelial cell migration GO:0043536 9.76 VEGFA KDR FGF2
19 positive regulation of mast cell chemotaxis GO:0060754 9.76 VEGFD VEGFB VEGFA PGF
20 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.75 VEGFA KDR FGF2
21 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.74 VEGFA KDR FLT1
22 positive regulation of sprouting angiogenesis GO:1903672 9.73 VEGFA TJP1 FGF2
23 cell migration involved in sprouting angiogenesis GO:0002042 9.72 VEGFA KDR FGF2
24 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.67 VEGFA FLT1
25 embryonic digestive tract development GO:0048566 9.66 TGFB2 CXCL8
26 positive regulation of phospholipase C activity GO:0010863 9.65 FLT1 FGF2
27 induction of positive chemotaxis GO:0050930 9.65 VEGFD VEGFB VEGFA PGF CXCL8
28 positive regulation of positive chemotaxis GO:0050927 9.64 VEGFA KDR
29 negative regulation of cell-cell adhesion mediated by cadherin GO:2000048 9.63 VEGFA PLG
30 sprouting angiogenesis GO:0002040 9.63 VEGFD VEGFB VEGFA PGF KDR FLT1
31 vascular wound healing GO:0061042 9.62 VEGFA KDR
32 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.6 VEGFA KDR
33 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.59 VEGFA KDR
34 positive regulation of angiogenesis GO:0045766 9.56 VEGFD VEGFB VEGFA PGF KDR FLT1
35 vascular endothelial growth factor signaling pathway GO:0038084 9.1 VEGFD VEGFB VEGFA PGF KDR FLT1

Molecular functions related to Neovascular Glaucoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 10 VEGFD VEGFB VEGFA PGF KDR FGF2
2 cytokine activity GO:0005125 9.73 VEGFA TGFB2 FGF2 CXCL8
3 growth factor activity GO:0008083 9.63 VEGFD VEGFB VEGFA TGFB2 PGF FGF2
4 heparin binding GO:0008201 9.62 VEGFB VEGFA PGF FGF2
5 platelet-derived growth factor receptor binding GO:0005161 9.48 VEGFD VEGFA
6 vascular endothelial growth factor binding GO:0038085 9.4 KDR FLT1
7 vascular endothelial growth factor-activated receptor activity GO:0005021 9.37 KDR FLT1
8 chemoattractant activity GO:0042056 9.35 VEGFD VEGFB VEGFA PGF FGF2
9 vascular endothelial growth factor receptor 1 binding GO:0043183 9.26 VEGFB VEGFA
10 vascular endothelial growth factor receptor binding GO:0005172 8.92 VEGFD VEGFB VEGFA PGF

Sources for Neovascular Glaucoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....